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Abstract: The main treatment of asthma is inhaled corticosteroids. However adherence to these
medications in asthma is often poor, with low adherence associated with excessive health care costs and
an increased risk of emergency room visits and mortality. Although various methods are used to
indirectly assess adherence, all have significant limitations whether used in clinical or research practice.
The recent development of electronic monitoring devices (EMDs) for use with inhalers presents an
exciting opportunity to easily and accurately measure inhaler adherence. This article summarises the
current devices available; for each device features and limitations are considered, followed by a review
of both the current clinical literature and data on reliability and accuracy. An overall summary is also
provided to aid comparison of capabilities between devices and future issues pertaining to the use of
EMDs are discussed, including barriers to adoption, stakeholder involvement, novel methods of
communicating adherence data, recording of data and cloud storage. Finally key areas that still require
investigation are highlighted.
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INTRODUCTION
Cost of Asthma
Asthma is a chronic respiratory condition with symptoms
including wheezing, dyspnoea and cough. A patient is
diagnosed with asthma based on the presence of such
symptoms together with evidence of variable airflow
obstruction or airway inflammation [1]. The U.K. has one of
the highest prevalence rates in the world with around 6% of
the general population diagnosed with asthma [2]. Similarly,
in the U.S.A, statistics from 2009 indicate that asthma
prevalence stands at 8.2%, equivalent to roughly 24.6 million
people, accounting for 10.5 million missed school days and
14.2 million sick days at work [3].
The direct costs associated with asthma present a
significant burden on society and healthcare systems. In the
UK current estimates highlight an annual care cost of around
£1 billion [2]. Furthermore it is estimated that the total
incremental cost of asthma to society in the USA is $56
billion [4]. This is despite asthma being a highly treatable
condition with effective medication available to reduce
symptoms and prevent asthma attacks [5].
The Problem of Non-Adherence in Asthma
It is easily arguable that poor adherence is the most
pressing issue in the proper management of asthma. There is
robust evidence that adherence to asthma treatment is
variable and often poor. Rates of non-adherence tend to
range from 30% to 70% [6], whereas for optimum control of
asthma, and thus minimum healthcare costs, a patient is
normally required to adhere to 80% or more of their
prescribed medication [7].
A study over 30 years of 30,569 people with asthma aged
from 5 to 44 years found a significant correlation between
increased use of inhaled corticosteroids (ICS) and a
decreased risk of death from asthma [8]. Similarly, a study
over 7 years with 12,301 children and adults with asthma
aged 5-54 found a significant positive correlation between
overuse of short-acting beta agonists (SABA) and asthma
mortality [9]. This clearly highlights the importance of
adhering to prescribed treatment for asthma. If a patient
properly uses ICS, research suggests there is a reduced risk
of death from their asthma. However, if a patient does not
adhere to their ICS and instead relies on their SABA to
relieve severe symptoms, they may be at an increased risk of
death.
The risks of non-adherence have made measuring and
investigating ways of improving adherence a priority for
researchers and clinicians alike [10].
Methods of Measuring Adherence in Asthma
Various methods have been used to monitor adherence in
asthma, the simplest of these being to directly ask the patient
how adherent they have been. Whilst self reported measures
can be a useful and intuitive method of receiving feedback
on a medical regime [11], it has been shown to be unreliable,
with patients estimating their adherence as 80% compared to
a true adherence rate of 50% [12]; in some cases full
adherence is reported, when adherence is actually 0% [13].
Canister weighing has been extensively used as a method
of measuring adherence. Here, the weight of an inhaler
canister at the point of prescription is compared with the
weight of the same inhaler canister when it is returned by the
patient in order to calculate an adherence score [14]. Whilst
this is relatively simple and easy to implement, canister
weighing has a number of major pitfalls, the most significant
being an inability to provide precise data on patterns of
inhaler use, meaning exact information on a patient’s asthma
treatment cannot be obtained. As a result of this imprecision,
canister weighing is also unable to detect ‘dose dumping’
[15], when a patient deliberately actuates their inhaler
multiple times consecutively over a short period of time in
order to give the appearance of optimal adherence to the
clinician or researcher [14].
Pharmacy database records have been used as a source of
information on adherence, providing data on type of
medication, amount prescribed, and refills. However, there
are similar issues to canister weighing with a low level of
data granularity meaning the total number of administered
doses is estimated over weeks or months, rather than hours or
minutes [14] and ‘dose dumping’ remains undetectable.
Research has shown pharmacy records to be less accurate
than both electronic monitoring and canister weighing [16].
Another way to detect non-adherence is through use of
fractional exhaled nitric oxide (FENO) [17]. Through directly
observed inhaled steroid therapy over seven days adherent
patients can show a greater reduction in FENO . This method
can serve as an objective test to distinguish between difficult
asthma and asthma in patients who are non-adherent to their
ICS therapy, who may fill in prescriptions yet fail to take
their medication [17].
Although barriers currently exist to their widespread use,
electronic monitoring probably offers the most accurate
practical measure, and the measure by which other methods
should be compared [12,18,19]. Although devices for other
types of inhaler exist, it was decided that this article would
focus on devices for standard metered dose inhalers (MDI) as
this is where the majority of research and development has
occurred.
ELECTRONIC MONITORING DEVICES (EMD)
For the purposes of this article EMDs will refer to devices
for monitoring use of MDIs, it will not refer to other devices
for use in asthma treatment such as electronic spirometers.
The devices described below all have at least one feature in
common; they record actuations of an MDI. Specific criteria
such as their ability to record the date and time of dose,
battery life, memory capacity, and a visual display for
feedback of last dose taken or doses taken over time are also
discussed. Where literature and data are available, important
information on how accurately the device can keep a record
of actuations, a percentage of devices that fail, and use of the
device in a clinical trial are also mentioned.
Nebulizer Chronolog
Fig.(1). A Nebulizer Chronolog (left) alongside an inhaler
(right) in its usual plastic holder that the Nebulizer
Chronolog replaces [20] (image included with permission
from BMJ Publishing Group Ltd.).
The Nebulizer Chronolog (NC) (Fig.1.) was developed
by Forefront Engineering Corp, Denver, Colorado, USA [21]
and was the first device to gain FDA (Food and Drug
Administration) approval as a monitoring device for asthma
[22]. The NC replaces the usual plastic casing surrounding
the inhaler canister, allowing for the canister to be used
within the NC’s own casing and mouthpiece [20].
The NC records actuations of the inhaler through a
micro-switch that is activated every time the inhaler is used.
The date and time of each actuation are recorded, with the
ability to store roughly 4,000 actuations in the devices
memory [21]. Data can then be uploaded to a Personal
Computer (PC) for analysis [19].
Features
 Records date and time of actuations
 It can be used with any aerosol inhaler canister [20]
 Data from the NC can be uploaded to a PC
 Food Drug Administration (FDA) approved [22]
Limitations
 Only compatible with a press-and-breathe metered
dose inhaler (MDI), not compatible with a breath
activated inhaler [21]
 Not compatible with spacers
 Does not detect inhalation
 Does not detect shaking of inhaler
 Does not record data on technique nor provide
feedback to patient on this
 No feedback screen, data can be only be viewed
once uploaded to a PC.
 Increases the size of the inhaler
Relevant Literature
The NC was utilised in a three-month pilot study
investigating adherence in fourteen children with asthma on
prophylactic treatment [20]. The NC demonstrated underuse
of medication and showed how one participant actuated their
inhaler 77 times in just thirteen minutes, demonstrating the
NC’s ability to indicate dose-dumping [20]. A further study
using the NC found an average median adherence of 77%
[23]. The authors noted that the majority of participants
found the NC acceptable, but two participants struggled with
fitting their inhaler canister fully into the device [23],
suggesting design limitations.
The reliability of the NC was tested alongside a newer
monitoring device, the Doser, in two trials [24]. In the first
trial lasting 4 weeks (but NC only tested for latter two
weeks), the NC was found to be 93% accurate in comparison
to manual recordings when actuated twice daily in a lab
setting by clinical personnel. However, in the second trial
lasting 4 weeks (but NC only tested for first or last two
weeks of study) accuracy was 80% compared to patient self-
report. Across the two studies, nine of the 48 NCs
malfunctioned, with loss of data [24].
Research using the NC has also investigated the effect of
providing patients with feedback on their medication use.
The majority of literature on the NC comes from research as
part of the ‘Lung Health Study,’ a five-year clinical trial
investigating whether smoking cessation and bronchodilator
medication can help prevent or delay the degradation of lung
function in smokers with Chronic Obstructive Pulmonary
Disease (COPD) [21]. A study of 251 adult cigarette smokers
with mild to moderate airflow obstruction found that
participants provided with feedback on their adherence
through recordings by the NC actually improved in their
adherence, compared to controls with no feedback [21].
Another aspect of the Lung Health Study conducted over
a four-month period found that when not informing
participants about the recording capabilities of the NC, 18%
of subjects dose-dumped their inhaler. This ‘dumping’
phenomenon was removed once participants were informed
[25]. A dumping phenomenon was recorded again by the NC
in a further study, where 30% of a sample of 101 participants
actuated their inhaler more than 100 times in a three hour
period [15]. Another study using self report over a four
month period found that of 95 participants, 73% stated they
used their inhaler three times a day on average, yet NC data
for 70 of these participants showed only 15% actually used
their inhaler 2.5 or more times on average per day [26].
MDILog
Fig.(2). An MDILog device (white box) attached to the back
of a normal metered dose inhaler (MDI) [27] (image
included with permission from Elsevier).
The MDILog (Fig. 2.) was developed by Westmed
Technologies Inc, Englewood, Colorado, USA [19]. The
MDILog attaches onto the back of the plastic casing of a
standard MDI [28].
The device is capable of recording actuations through a
mechanical beam with a strain gauge, shaking of the inhaler
with a movable magnet, and actual inhaling through a heated
thermistor [22]. For each of these three sources of data, the
date and time are recorded [22]. The device can store 1300
data logs in total [28], which can later be transferred to a PC
using an infrared port, or wirelessly using a modem to
transfer data directly from a patients home [28].
Features
 Records date and time of actuations
 Detects inhalation and shaking of inhaler
 Has a battery life of 6 months [22]
 Has an LCD display that shows feedback on
adherence, or can alternatively be masked to limit
feedback [29]
 Compatible with spacers
 Has an auditory tone that beeps to remind patients
to use their inhaler, and beeps when a canister is
empty [22]
 Data can be transferred via infrared port or modem
 FDA approved [22]
Limitations
 Cannot be sterilized to be used across multiple
patients [28]
 Only compatible with a standard MDI
 Does not provide feedback to patient on inhalation
technique
Relevant Literature
The reliability of the MDILog as a device has been tested
across multiple studies. By comparing MDILog data with
diary reports, one study found that 1200 actuation recordings
for all three MDILog devices were 97%-100% accurate,
inhalation was 82%-100% accurate and shaking
identification was 86% to 95% accurate [27]. Another study
tested 6 MDILog devices but found that one device
repeatedly malfunctioned [30] and a further study compared
the MDILog’s reliability to two other devices by actuating
two MDILogs twice daily for 30 days [31]. They found an
accuracy of 90.1%, with occasional spurious recordings
being noted. The researchers concluded the device is
sufficiently accurate for monitoring adherence in clinical
settings [31].
The MDILog has also been used in two different studies
measuring adherence. The first found in a sample of 106
children with asthma that adherence over a month was 48%
on average [32]. Similarly the second found a median
adherence of 46% over one month in 75 children with
asthma aged 8 to 16 [33].
Doser
Fig.(3). A Doser (right) attached to the top of an inhaler
canister (left) [24] (image included with permission from
Elsevier)
The Doser (Fig. 3.) was developed by Meditrack Inc,
Hudson, Massachusetts, USA [12]. The device is round and
flat in structure and fits on top of a standard MDI canister, it
also has an LED display to see feedback on adherence [31].
The Doser records actuations through an
electromechanical switch that is activated when the user
applies adequate pressure to the top of the inhaler, instigating
actuation [34]. The device contains two different counters,
one to count down the number of actuations remaining in the
canister and another to count the number of actuations on a
single day [31]. The second counter resets itself at midnight
and stores the total number of actuations for each day in its
internal memory [31]. The device will beep to tell a patient
when an actuation has been recorded and also beeps when a
canister is nearly empty [34]. Data cannot be downloaded
from the device, it can only be written out manually [31].
Features
 Has ‘Covert’ and ‘Overt’ modes for LED display so
feedback can be hidden if necessary [34]
 Battery life of 12 months [22]
 Beeps when there are fewer than 20 actuations left
to alert patient that their canister is shortly in need
of replacing [22]
 Compatible with spacers
 FDA approved [22]
Limitations
 Does not record date and time of actuation [31]
 Cannot upload data to a PC for review [31]
 Data is only stored for 30 days
 The battery cannot be replaced [22]
 Possible incompatibility with newer types of MDI
canister [34]
 Does not detect inhalation [28]
 Does not detect shaking of inhaler
 Does not record data on technique nor provide
feedback to patient on this
Relevant Literature
The reliability of the Doser has been extensively tested. A
test of accuracy against two other monitoring devices for 30
days found two Doser devices to be 94.3% accurate with
occasional recording of spurious actuations [31]. They also
found the counter for amount of inhalations left in the
canister sometimes went to zero prematurely [31]. A further
study conducted three separate tests of reliability and found
Doser accuracy ranged from 94%-97% [24]. Accuracy of
100% was reported in a study using 6 devices over 30 days
[35], but another study using 16 Dosers over 61 months
found that 8% had mechanical faults such as an unreadable
display, battery failure and error messages [36].
A study of 27 children with asthma compared the Doser
(301 devices used in total) as a measure of adherence against
three other methods; self-report, mother report and canister
weight [12]. Over six months, they found that child and
mother reports on average gave adherence rates of 80%,
canister weighing produced average adherence rates of 69%,
but Doser devices reported average adherence rates of just
50% [12]. This led the authors to conclude that electronic
monitoring is a significantly more accurate method of
collecting data on adherence than self-report or canister
weighing. However, the researchers stated that 61 (21%) of
the Doser devices failed to retrieve data from their internal
memory to be displayed on their LED screen [12].
SmartMist
The SmartMist was developed by Aradigm Corporation,
Hayward, California, USA [37]. The SmartMist is a large
device that encases nearly the entire MDI within it, leaving
only the mouthpiece of the inhaler exposed [31]. It is
compatible with standard MDIs [37].
The SmartMist records the date and time of every
actuation [31]. Actuation of the inhaler occurs through
inhalation; a plunger within the device pushes downward on
the inhaler canister once a specific inspiratory flow rate (25
to 60 L/min) and volume (250 to 500mL) have been reached.
[31]. As well as using its microprocessor and solid-state
memory for recording actuations, inhalation flow is recorded
before, during and after every use [38]. It can provide instant
feedback on inhalation technique whilst a dose is being
administered by displaying a flashing red light when
inhalation is too rapid, a solid green light when inhalation is
good and no light when inhalation is too weak [31]. This
benefits adherence data as it can help indicate when doses
have been taken but technique is good or poor. This can help
a clinician or researcher to understand if poorly controlled
asthma is associated with poor adherence or poor technique
[31].
Data are transferred from the device to a PC via cable and
from here it can be printed off so it can be viewed in a list or
graph [31].
Features
 Records and provides instant feedback on inhalation
technique [31]
 Records date and time of actuations
 Actuations are recorded through inhalation,
preventing a patient from dose dumping using the
device
 Data can be transferred to a PC
 FDA approved [39]
Limitations
 Large device, significantly increasing the size of the
usual MDI
Relevant Literature
The reliability of the SmartMist was investigated in
comparison to two other monitoring devices (MDILog and
Doser as already mentioned) in a 30-day study where 6
SmartMist devices were actuated twice daily [31]. The
researchers found that the SmartMist was 100% accurate
with all actuation logs matching written recordings. This
makes it the most accurate of the three devices. The authors
suggested that due to the SmartMists excellent accuracy, it
could potentially be useful in clinical research [31].
Smart Inhaler Tracker (Smart Inhaler Generation 1)
Fig.(4). A Smart Inhaler Tracker with canister inserted.
(image included with permission from Nexus 6,
www.smartinhaler.com/).
The Smart Inhaler Tracker (Fig. 4.) was developed by
Nexus 6, Auckland, New Zealand [40]. The device consists
of a plastic casing, with slightly different shapes available for
different medication canisters [40]. The device maintains a
similar shape to that of a normal MDI casing, with a larger
size to allow room for the battery and electronics [35].
When a patient presses downwards and applies pressure
to their inhaler, the canister connects with a switch within the
device, resulting in the recording of a time and date stamp
for the actuation [34]. This process happens for every
actuation of the inhaler, with the device capable of recording
1600 data logs in total [34]. Actuation recordings can be
transferred to a PC through a USB (Universal Serial Bus)
cable, where ‘connection centre’ software takes data from the
device and uploads it to an online database where it is kept in
password protected storage, to be viewed by either the
patient, clinician or researcher or other person with granted
access [40].
Features
 Records date and time of actuations
 Different shaped cases available for different
medication canisters
 Compatible with spacers [41]
 Reusable [34]
 Data can be transferred to PC via USB
 Audio Visual Reminder Function (AVRF) can be
built in to provide feedback to patient and remind
them to use their inhaler. Alarm can beep every 30
seconds for up to 60 minutes and LED light can
display green light before actuation and red light
after [42]
Limitations
 Needs specific casings designed for specific drugs
and is therefore not a generic monitor that fits all
MDIs
 Does not detect inhalation [43]
 Does not detect shaking of inhaler
 Does not record data on technique nor provide
feedback to patient on this [43]
 No display to provide detailed visual feedback on
when last dose was taken, or how many doses have
been taken in total.
Relevant Literature
A number of studies have assessed the reliability of the
Smart Inhaler Tracker. In one study, 10 Smart Inhaler
Trackers were tested through the researchers actuating them
twice daily for 30 days [35]. They found five to be 100%
accurate, but one failed to record the very first dose and the
remaining four all failed to record the first two doses.
However, after the first two doses all 10 were 100% accurate
with no spurious recordings. It was later discovered that the
failing of some devices to record the first one or two doses
was due to the canister not being inserted far enough into the
device [35]. The same study also tested the Smart Inhaler
Tracker’s ability to indicate dose dumping, by taking 6
devices and actuating each 30 times in a row over a very
short period. They found all to be 100% accurate [35].
A prolonged study in contrast to other short-term
validation studies tested the accuracy and reliability of the
Smart Inhaler Tracker over a 24-week period [44]. The
authors tested 22 devices in total at 0, 8, 16 and 24 weeks by
simulating both low use (two actuations separated by 10-20
seconds each) and high use (eight actuations separated by 10-
20 seconds each). They found overall accuracy in recording
the number of actuations was 99.7% and accuracy in
recording the date and time of actuations was 99.3% [44].
An extensive study found that of 2642 Smart Inhaler
Trackers dispensed, 2498 (94.5%) successfully connected to
a PC and uploaded a complete data set [40]. Furthermore of
2549 devices returned by patients, 2498 (98%) successfully
uploaded complete data sets. Devices that failed were mostly
due to fluid immersion. The authors concluded that the Smart
Inhaler Tracker is a sufficiently reliable monitoring devices
to be used for measuring adherence in real-world settings
[40].
One study used the Smart Inhaler Tracker in a feasibility
test of bronchial hyper-responsiveness (BHR) to manage
asthma [45]. 14 adults with asthma had their ICS use
monitored and were tested for BHR on three separate
occasions over size weeks. They found that 2 of the 10 Smart
Inhaler Trackers they used failed to upload data (20%). They
also received feedback from patients about devices that could
be used to monitor their medication use. One patient stated
“Knowing that it was recording dosing time made me more
conscious of taking (my) medication” whilst another said
“Knowing someone is going to check the (dosing) times
makes you comply” [45].
The Smart Inhaler Tracker has been utilised in a number
of studies investigating adherence in asthma. A 24 week
randomized controlled trial with 111 patients with asthma
aged 16-65 investigated whether a combination inhaler
containing ICS and long acting beta agonists significantly
improved adherence compared to separate standard inhalers
[46]. The Smart Inhaler Tracker was used to monitor
adherence and over the final 6 weeks of the trial found no
significant difference in adherence between patients on
combination therapy or separate [46].
An investigation into the effect of an audio-visual
reminder on adherence in 110 participants with asthma aged
12-65 found that after 12 weeks adherence was significantly
higher in the audio-visual reminder condition (93%) than in
the control group (74%) suggesting that the Smart Inhaler
Tracker with this capability to remind patients enabled, may
actually help improve adherence as well as record it [42].
A study of 51 children with asthma compared adherence
recorded through the Smart Inhaler Tracker to adherence as
reported by parents and in questionnaires they were required
to complete on their child’s medication taking [18]. Parental
reports (85.1%) and questionnaires (84.2%) both
significantly overestimated inhaler use as average adherence
rates were shown by the Smart Inhaler Tracker to be 70.5%
[18]. A recent study of 93 children found a median adherence
of 92% over 3 months using the Smart Inhaler Tracker with
94% of parents stating that regular inhaler use would prevent
their child from getting worse [47]. This finding of high
adherence was likely to be due to the education and follow
up of the participants [47].
SmartTrack (Smart Inhaler Generation 2)
Fig.(5). A SmartTrack device (black) clipped around a
standard MDI (purple). (Image included with permission
from Nexus 6, www.smartinhaler.com/)
The SmartTrack (Fig. 5.) was developed by Nexus 6,
Auckland, New Zealand [34]. The device securely clips
around a standard MDI and consists of an LCD screen
capable of displaying information about medication taken,
battery level and various settings. Surrounding the device are
4 square buttons that can be pressed to navigate through the
device’s interface. Like its predecessor, different shaped
devices are available for different medication types [34].
The SmartTrack records the date and time of actuations,
MDI insertion/removal and setting changes such as turning
reminders on/off [48]. Actuations are recorded using an
optical dose counter [49]. A light transmitter and light
receiver and placed at opposite ends of the inside of the
device, both below the canister. When the inhaler canister is
depressed, it blocks the light from the transmitter reaching
the receiver, allowing for the dose counter to register this as
an actuation and create a date and time stamp to accompany
it [49].
Data can be transferred from a SmartTrack to a PC via a
USB cable where ‘connection centre’ software takes data
from the device and uploads it to an online database where it
is kept in password protected storage, to be viewed by either
the patient, clinician or researcher or other person with
granted access [34,40]. Data from the SmartTrack can also
be viewed on the ‘SmartinhalerLive’ smartphone application,
which can display adherence data in graphs or tables to allow
the viewer to see inhaler use and missed doses over a period
of time.
Features
 Records date and time of actuations, canister
insertion/removal and turning reminders on/off
 Different shaped devices are available for different
types of medication
 Compatible with spacers
 Reusable
 LCD screen to display feedback to the patient on
when their inhaler was last used, battery life and
settings
 Choice of ringtones available for auditory reminders
[34]
 Data can be transferred to a PC where it can then be
viewed on an online database or on a smartphone
 FDA approved [50]
Limitations
 Does not detect inhalation
 Does not detect shaking of inhaler
 Does not record data on technique nor provide
feedback to patient on this
 Adds significant bulk to a standard MDI
Relevant Literature
To date, only one published study has used the
SmartTrack device. This study assessed both the reliability of
the SmartTrack as well as patient attitudes towards it [48].
Three reliability tests were performed. The first test
investigated the accuracy of actuations logs and device
functions such as ringtones at correct reminder times,
displayed information on ‘last puff taken’ and the data/time
on the device. They found 9/10 devices performed all tasks
100% accurately, with one device failing to record any
actuations or any canister insertions/removals. The second
test simulated actual patient use in the nine fully working
devices by actuating two puffs twice a day for two days,
followed by mimicking dose dumping by actuating 30 doses
in quick succession. They found 6/9 devices to be 100%
accurate, with one device having inaccurate actuation times
compared to diary entries and the remaining 2 devices
experiencing minor errors deemed as ‘acceptable’ to the
researchers [48].
The final test consisted of the eight still fully operational
SmartTrack devices being assigned to eight adults with
asthma [48]. Participants were instructed to take their
medication at their usual frequency and to record in a diary
whenever they actuated their inhaler for seven days. Overall
accuracy of actuations recordings for this period was found
to be an average of 95.6% for the 8 devices. The six
SmartTracks that had been set up to remind patients all
successfully rang on time and were all silenced appropriately
[48].
This study also asked for feedback from participants in
the third test on their attitudes towards the SmartTrack
device [48]. All patients rated the device as easy to use.
Some of the comments provided by participants included
“Buttons are small and sometimes hard to register”, “I quite
liked having a reminder”, “It was a bit bulky to take away for
a weekend” and “(Reminders) rang too regularly perhaps
once every 5-10 minutes; short ringtones were good” [48].
SmartTouch AV (Smart Inhaler Generation 3)
Fig.(6). A SmartTouch AV device (white) clipped around a
standard MDI (red). (Image included with permission from
Nexus 6, www.smartinhaler.com/)
The SmartTouch AV (Fig. 6.) was developed by Nexus 6,
Auckland, New Zealand [51]. The device clips around a
standard MDI in the same way as its predecessor the
SmartTrack, meaning it simply fits around the usual inhaler
casing which houses the canister [51]. The device consists of
a touch-screen display capable of providing information on
medication use, time, battery level and settings such as
notifications. The touch-screen allows for the user to directly
interact with the display through pressing icons, rather than
by pressing buttons next to the display as is seen on the
SmartTrack [51]. Like the first and second generation Smart
Inhalers, different shaped devices are available for different
medications [51].
The SmartTouch AV records the date and time of every
actuation [51]. Actuations are recorded using the same
process as the SmartTrack inhaler, an optical dose counter
consisting of a light transmitter and light receiver are placed
within the device [49]. When the inhaler canister is
depressed, this breaks the light between the transmitter and
receiver, resulting in the dose counter recording this as an
actuation along with the date and time [49]. The SmartTouch
AV has a memory capable of storing up to 4096 actuation
logs [51].
Data from the SmartTouch AV is transferred to an online
database where it is stored in password protected storage
[52]. Data can be transferred through three methods; firstly,
the ‘Smart Hub’ can be placed in a patient’s home and
requires no existing Internet connection due to a built in
modem [52]. Data is automatically transferred using the
Smart Hub whenever a SmartTouch AV is in range.
Alternatively, data can be transferred using the ‘Smart Key’,
a USB peripheral that can be plugged into an internet-
connected PC via a USB port. This works in the same way as
the Smart Hub and uploads adherence data whenever the
SmartTouch AV is in range. The final method for uploading
data is via ‘Smartinhaler Mobile’, the dedicated Smartinhaler
application for smartphones and tablets. The Smartinhaler
Mobile application pairs a phone or tablet with a SmartTouch
AV device through a Bluetooth connection, allowing for
automatic uploading of data whenever the two devices are in
range of each other and the phone or tablet has internet
access [52]
As mentioned, the SmartTouch AV device can be
accompanied by the Smartinhaler Mobile smartphone
application [52]. This allows for a patient’s smartphone to
display information on a patients inhaler use over a period of
time such as a week or a month. It also allows for a patient to
stay updated on their inhaler use through a device that would
not usually be associated with their asthma, instead of a
through a feedback system attached to their inhaler. The
Smartinhaler Mobile application is currently available for
iPhone, iPad and Android devices [52].
Features
 Records date and time of actuations, canister
insertion/removal and turning reminders on/off
 Different shaped devices are available for different
types of medication
 Compatible with spacers
 Reusable
 Battery life of 1-3 months depending on usage
 Has a touch-screen to display feedback to the
patient on when their inhaler was last used, battery
life and settings and to allow for the patient to
directly interact with the device interface
 Different ringtones available for customisable
reminders [52]
 Multiple methods for automatically and wirelessly
transferring adherence data
 Dedicated Smartphone application capable of
transferring and uploading data and displaying
feedback on adherence.
Limitations
 Does not detect inhalation
 Does not detect shaking of inhaler
 Does not record data on technique nor provide
feedback to patient on this
 No published peer-reviewed literature on accuracy
Relevant Literature
No relevant literature currently available.
Propeller (Formerly Asthmapolis)
Fig.(7). A Propeller device (white) attached to the top of the
canister of a standard MDI. (Image included with permission
from Propeller Health, www.propellerhealth.com)
The Propeller device (Fig. 7.) was developed by Propeller
Health, Madison, Wisconsin, USA [53]. The Propeller device
is a circular cap that ‘snaps’ onto the top of a standard MDI
canister [54]. This cap can be adjusted for different sized
canisters by adjusting the position of the sensor slightly to
achieve a tight fit [54]
The Propeller device records the date and time of every
actuation using it’s internal clock and also records the GPS
(Global Positioning System) location [54]. Actuations are
initially registered and identified by the device through the
use of a magnet and magnet sensor [55]. When the inhaler
canister is depressed, this brings the magnet within the
device towards the magnet sensor. When the magnet and
sensor touch, this acts as a switch and results in a voltage
change in the device, which is then recorded as an actuation
along with a date/time and GPS stamp [55].
The Propeller device can transfer adherence data in three
different ways [54]. Firstly, via Bluetooth connectivity to a
smartphone with data automatically and wirelessly uploaded
via the patient’s phone to the Propeller Health online
database. The patient can then receive feedback on their
adherence by viewing information on their smartphone using
the dedicated Propeller Health smartphone application [54].
However, if the patient does not have a Smartphone, a ‘hub’
can be placed within their home to be paired with their
Propeller device to automatically upload adherence data. For
these patients, they can receive feedback on their adherence
through e-mail. If a patient does not have e-mail, they can
receive feedback by phone call. If there is neither a
smartphone nor a ‘hub’ within sufficient proximity of a
Propeller device, it will hold the data in its memory (which
can hold up to 3900 logs) until a smartphone or ‘hub’ is
available to transmit data to [54].
The Propeller Health smartphone application is a key part
of the Propeller system, as the Propeller device itself does
not have a display or any buttons [53]. The smartphone
application is available on the App store for iOS devices
(iPhone and iPod touch) and on the Google Play Store for
various Android devices. The application is available in both
English and Spanish, but is currently only available for
download in the USA. The application can display
information to a patient in a visual form, such as trends of
use, date/time and location of actuations [53]. The
application also sends a message to the patient when they use
their rescue medication such as “We see you used your
rescue medication. We hope you’re okay, when you’re
feeling better, enter your trigger information. Like were you
near a cat, was there mould, or was it cold outside?” this
helps build a record of specific triggers for a patient’s
asthma, with the aim of improving patients self-management
of their asthma over time [53].
Features
 FDA and Health Insurance Portability and
Accountability Act (HIPAA) approved [53]
 Records date and time of actuations
 Records GPS of actuations
 Compatible with spacers
 Reusable [34]
 Suitable for users with/without smartphones and
with/without email
 Battery life of 40 days (recharged via USB
connection) [54]
 Feedback on adherence via smartphone or email
 Prompts to patients to describe triggers via
smartphone application
 Sends messages to patient to educate on better
inhaler use, helping them to understand particular
triggers for their own asthma based on previous
inhaler use recorded by the device.
Limitations
 Only available in the USA
 Does not detect inhalation
 Does not detect shaking of inhaler
 No published peer-reviewed literature on accuracy
 Does not record data on technique nor provide
feedback to patient on this
Relevant Literature
Research using the Propeller device is still in its infancy.
A pilot study using an earlier version of the Propeller sensor
with 30 participants found that after 4 months using the
device and receiving feedback on their asthma management,
75% of the participants had an Asthma Control Test (ACT)
score of 19 or above (19 being controlled asthma) [56]. At
the beginning of the study, only 38% had such an ACT score
[56].
An on-going study is also being carried out with 498
asthma patients in California, USA, where the latest
Propeller sensor has been assigned to half the participants
[57]. No results have been published so far, although the
researchers have reported that participants using the
Propeller device are on track to save an average of $700 in
healthcare costs in comparisons to the previous year [57].
Table 1. Summary of features for EMDs in asthma treatment
Device Re-usable FDA
approved
Spacer
Compatible
Records
Date and
Time of
Actuation
Detects
Inhalation
Detects
Shaking of
Inhaler
Record and
Feedback
Information
on Inhalation
Technique
Reminders
for Patients
Records
GPS
Location
of
Actuation
Device
Screen to
Display
Information
Data
Transferable
to PC/Online
Storage
Dedicated
Smartphone
Application
Nebulizer
Chronolog
✓

 ✓ ✓
MDILog ✓

✓

✓ ✓ ✓


✓ ✓
Doser ✓ ✓
Beeps for
canister
nearly
empty
✓
SmartMist Info. notavailable
✓ Info. not
available
✓ ✓ ✓ ✓ ✓
Smart Inhaler
Tracker
✓ Info. not
available
✓ ✓
 
✓ ✓
SmartTrack ✓ ✓ ✓ ✓
 
✓ ✓ ✓ ✓
SmartTouch
AV
✓ Info. not
available
✓ ✓
 
✓ ✓ ✓ ✓
Propeller ✓ ✓ ✓ ✓ ✓ ✓ ✓
Other devices
There are notable examples of devices built for inhalers other
than a standard MDI. The INCA (Inhaler Compliance
Assessment) device was developed by Vitalograph Ltd and is
compatible with a DiskusTM inhaler (AccuhalerTM in the
U.K.) [58]. This device uses a microphone to record acoustic
signals capable of detecting peak inspiratory flow rate
(PIFR) and actuations in patients. Like other devices this
data can later be uploaded to a PC via USB connection and
software can be used to calculate date and time of doses [58].
The INCA device can measure both temporal adherence as
well as technique [59]. Validation of this device has been
carried out in 69 patients with asthma where a close
correlation was found between audio recordings of dose and
doses taken. Further investigation demonstrated a close
correlation between acoustic energy of exhalations into the
inhaler device and the amount of drug removed in that
particular dose [59].
Another device is the Diskus Adherence Logger (DAL), this
device consists of a small postage stamp sized module that is
attached to the outside of a Diskus inhaler [60]. It detects
whenever the Diskus lever is pushed into the correct position
for actuations. The DAL device itself can be inserted into a
USB port on a PC, allowing data to be transferred to
dedicated software [60].
FUTURE ISSUES
Stakeholder Involvement and Intervention
A key issue to consider in adherence monitoring is to
whom the adherence data is available and the potential issues
this may cause. The Smart Inhaler and Propeller devices all
upload adherence data to an online database where it can be
viewed by any person with granted access; this could be the
patient, a family member, carer, friend or a medical
professional such as a GP or Asthma nurse [34,40,54].
In the case of a healthcare professional, this availability
of adherence data in a regularly updated form raises some
interesting questions about their involvement and
responsibility to intervene. Access to patient data allows a
medical professional to interpret how adherent a patient is to
their prescribed treatment with relative ease and in far greater
detail than through their clinic visits.
An example of where the value of adherence data at this
level of detail is demonstrated comes from a recent real
world asthma clinical trial using EMDs, in which adult
patients commonly both underused and overused their
inhaled treatments [61]. The authors reported extreme
overuse of beta-agonists (32 or more actuations a day) in 40
(26%) of their 152 participants on standard treatment [61].
This creates a number of potential issues, such as the
potential responsibility of a professional to intervene as well
as their chosen method for doing so. Furthermore an exact
threshold for both underuse and overuse of inhaled
medication needs to be established whereby a medical
professional has an obligation to intervene and contact the
patient.
Once it is established when and where an intervention is
necessary, the next consideration is what this intervention
should actually be. Many studies have demonstrated
interventions to improve adherence, such as education on
self-management and feedback of adherence data, but there
is little agreement over what is most effective and therefore
recommended [62]. Furthermore, it needs to be addressed
how the additional time spent using this adherence data for
interventional purposes could be suitably assigned by
commissioners and funders as separate from ‘standard’
asthma care. Successful uptake by health care professionals
may be unlikely without appropriate means to claim for extra
care costs [63].
As methods of intervening are determined, it is important
to also consider the health literacy of patients, carers, and
family for whom interventional information may be
communicated to; information must be portrayed in an easy
to understand way and accessibility to services such as the
Internet, computers and smartphones must be achieved.
Novel Methods of Communicating Adherence Data
With new information readily available on adherence to
asthma medication there is opportunity to improve
understanding of adherence by patients, but it is important to
consider how best to communicate this information. All the
devices discussed (apart from the Doser) are capable of
uploading data to a PC (see Table 1). This allows for
information to then be displayed as a graph or table, to either
be printed out or viewed on screen, so that a patient can
either review the data alone, or with another individual such
as their GP or asthma nurse.
This standard method of communicating adherence data
back to a patient has been used with some success with
studies reporting an improvement in patients at high-risk of
non-adherence [21,25,41,64]. However, it is important to
investigate new and alternative methods of feedback and
communication to attempt to utilise this wealth of data. With
the recent surge in smartphone based applications and
compatible devices for fitness and health [65] it appears a
natural progression for asthma research to explore the
potential for integration of smartphones in asthma treatment,
through utilising them as a method of communicating
feedback on adherence to patients.
Smartphone integration for asthma management has been
investigated [66–70] with mixed results. One six-month trial
of 288 adolescents and adults with poorly controlled asthma
found that smartphone based monitoring had no significant
effect on asthma control and self-efficacy in comparison to
paper based monitoring [69]. These were measured using the
asthma control questionnaire (ACQ) and the knowledge,
attitude, and self efficacy asthma questionnaire (KASE-AQ)
[69]. However in this study participants were required to
input their symptoms, drug use and peak flow readings
manually to either a smartphone or on paper, with an asthma
nurse contacting patients in the smartphone group with peak
flow recordings in ‘red’ or ‘amber’ zones [69]. This is
different to an EMD automatically syncing recorded data
with a mobile phone, such as in the SmartTouch AV and
Propeller devices. A similar study investigated the feasibility
of a text-based system as a method of generating daily
reports on a patient’s asthma [70]. Results showed a high
response rate to text messages of 81%-97% and
demonstrated that participants felt using the system helped
improve their awareness of symptoms as well as promoting a
greater sense of control and better adherence to their asthma
[70].
Along with the smartphone integration and automatic
syncing seen in the SmartTouch AV and Propeller devices,
another recent technology exists using a game-based system
based on an Android platform to reinforce adherence.
‘Geckocap’ [71] are a new start-up company who have
developed both a monitoring device to clip to the top of a
standard MDI, along with a smartphone application aimed at
children with asthma. The application automatically updates
with the most recent inhaler use and allows parents to set
goals and award prizes through the application for good
adherence. Similar approaches, attempting to ‘gamify’
improved health management include ‘MangoHealth’ [72]
and ‘PatientPartner’ [73].
Varying User Needs
When designing an EMD the needs of different patient
groups must be taken into consideration. This is particularly
the case in asthma which can affect children, adolescents and
adults. Moreover inhaler adherence is equally important in
Chronic Obstructive Pulmonary Disease (COPD), a
condition predominantly affecting the elderly. For example, a
smartphone application to work alongside the monitoring
device may be an effective system for adolescents, as recent
statistics show that in the UK around 81% of 12-17 year olds
own smartphones, with this figure predicted to rise to 96%
by 2017 [74]. However, only 13% of people aged 65+
currently own smartphones, with still less than half of this
portion of the population expected to own smartphones by
2017 [74]. It is important to recognise that whilst
smartphone integration could be a viable option for
technology-aware users, it should not be assumed that all
people will be comfortable or capable of using the same
technological solutions.
An example of where meeting the needs of different user
groups has been established is the Propeller device, where
feedback on adherence can be communicated back to
patients through a smartphone application, e-mail or phone
call [54]. This allows the system to cater for different needs
and recognises that different users may not have access to
certain technologies and services.
There is still a need to take the potential low socio-
economic status of users into account in the development and
provision of EMDs, particularly as technology becomes
more advanced. Expensive technologies may be unaffordable
and inaccessible for a portion of the target population [75]
and there is also evidence that health technologies may be
not be adopted as quickly by ethnic minorities [76]. This is
particularly important as certain ethnic groups may be
disproportionately affected by asthma [77] or may have
particularly poor asthma outcomes [78–80].
Barriers to Adoption
If EMDs were to be fully established in asthma care,
there are several potential barriers to be overcome. These
barriers include patient attitudes to treatment and
responsibility for data monitoring and protection.
Patient Attitudes
Research on EMDs to date has largely been clinically-
focused in nature. Although investigating the reliability and
accuracy of a monitoring device are essential, research and
development processes must also consider the user. This
would involve patient attitudes towards the devices including
factors such as their usability, their portability and
practicality, their social acceptability [81], and how
comfortable a patient would feel having their medication
taking behaviour recorded in this way. These are important
factors to consider for successful uptake and long-term use of
these devices, which have not yet been investigated..
The only notable examples where patient feedback has
been obtained are in a study using the Smart Inhaler Tracker
[45] and a study investigating the accuracy of the
SmartTrack [48]. However, even these studies simply
gathered this data as a secondary aim alongside their overall
main objective. Both studies also used samples of adult
patients. No research on EMDs for inhalers to our knowledge
has considered the attitudes of the age group where asthma is
most prevalent – children and adolescents.
Data Monitoring and Protection
Recording data on patient health and adherence to their
medical regimen is a sensitive source of information where a
suitable security and privacy framework is required. If data is
unsecure and is leaked or hacked this could have serious
consequences for the patient as personal and private
information could become available to employers, health
insurers or other individuals who would not usually have
granted access [82]. Furthermore, there could be severe
implications for either the responsible health professionals or
IT providers who could be charged with violating privacy
legislations and incur serious legal penalties as a
consequence [82].
With the integration of smartphones, wireless automatic
uploading of data, and online databases as seen in the
Propeller and SmartTouch AV devices, adherence data is
commonly being stored in the ‘cloud’. Although there is
debate over the correct definition of ‘the cloud’ it can be
described as a new paradigm for computing infrastructure
where the location of the infrastructure is changed from
being based in hardware and software to being based in the
network [83].
Storing sensitive and personal health information in the
‘cloud’ creates a number of issues. Firstly, although data can
be described as being ‘stored in the cloud’ the cloud itself is
run from a data centre. Sensitive health data stored here must
be sufficiently secured and protected through strong
cryptographic encryption so that it cannot be leaked from
within it [82]. Furthermore, the data centre is likely to
require maintenance, so a system needs to be established to
allow these processes to be achieved without an
administrator actually accessing the sensitive patient data
[82].
The second issue arises from the security of the PC and
network infrastructure of the end-user [82]. This could be the
patients home PC, a PC at a doctor’s practise or a PC at a
hospital or health centre. These systems often lack sufficient
protection and can be vulnerable to threats such as malware
attacks where passwords and data could be stolen and leaked
to other unidentified and unauthorised sources [82].
Although this can be an issue for patients, it could be
considered an even greater issue for doctors who are likely to
see multiple patients. Doctors who run their own practise
often lack both the time, knowledge and ability to maintain
and regulate effective security and protection for their own
IT infrastructure. This could therefore pose a serious risk and
sensitive data from multiple patients could be hacked and
leaked [82].
The third issue to consider relates to the use of
smartphones. With the introduction of smartphone
applications to wirelessly sync with monitoring devices such
as the SmartTouch AV and Propeller, this again relies on the
users own personal smartphone being free from viruses and
malware which could intercept or access adherence data
outside of the monitoring devices dedicated smartphone
application.
There is therefore a need to consider how patient data
should be stored and how it should be appropriately
protected and secured so that only those with granted access
to the information are able to privately view it.
Future Research
Although research to date has focused largely on the
reliability and accuracy of devices, there is still further work
required in this field as devices develop and gain new
features and capabilities. For example, the potential
relationship and benefit to adherence of the Propeller
devices’ ability to record the GPS location of actuations
remains un-tested. Furthermore, the ability of the
SmartTouch AV device and Propeller device to wirelessly
and automatically sync adherence data via Bluetooth to
various technologies such as smartphones and modems also
lacks published literature on its effectiveness and reliability.
Future work also needs to consider the user. Qualitative
research needs to specifically investigate the attitudes of
different user groups such as children, adolescents, adults
and the elderly to determine how the needs of these
populations differ and to help identify potential barriers to
adoption such as unease about recording of data and whom
data should be shared with. The attitudes of key stakeholders
in asthma management to EMDs needs establishing
including GPs, asthma specialists, asthma nurses,
pharmacists and commissioning groups. Determining how
these groups view monitoring in asthma is crucial for the
viable widespread adoption of the technology. Establishing
when and at what point stakeholders feel they have an
obligation to intervene with a patient, if this data on
adherence is available, is crucial.
The effect electronic monitoring may have on adherence
itself has been investigated previously, where it has been
shown EMDs can not only accurately record adherence but
improve it as well [21,25]. However, the differential effect of
being monitored alone versus being monitored and receiving
feedback has not been established. These two factors need to
be isolated and investigated in the same study with the same
sample to determine exactly how much each affects
adherence.
CONCLUSION
EMDs for asthma treatment are rapidly developing, and
will continue to develop, with new features including
smartphone integration, wireless data transfer, cloud storage
and GPS all advancing device capabilities and assisting
introduction of EMDs into everyday treatment for asthma
patients.
We have provided a review of EMDs and a summary of
the relevant literature relevant to their reliability and
accuracy. It has been highlighted that many other factors
related to these devices have so far been largely overlooked.
The needs and requirements of different user groups such as
children, adolescents and the elderly must be identified to
make EMDs compatible with their treatment. Furthermore,
access to data by key stakeholders in a patients asthma
treatment, the responsibility of these individuals to intervene
as well as the method of intervention need determining.
Sensitive information may be recorded by EMDs and further
work on how data is stored and protected is also of
importance.
These key issues when considering the uptake of EMDs
have been discussed in this review, including areas of future
research.
ABBREVIATIONS
ACQ = Asthma Control Questionnaire
ACT = Asthma Control Test
AVRF = Audio Visual Reminder Function
BHR = Bronchial Hyper Responsiveness
COPD = Chronic Obstructive Pulmonary
Disease
DAL = Diskus Adherence Logger
EMD = Electronic Monitoring Device
FDA = Food Drug Administration
FENO = Fractional Exhaled Nitric Oxide
GPS = Global Positioning System
HIPAA = Health Insurance Portability and
Accountability Act
ICS = Inhaled Corticosteroids
INCA = Inhaled Compliance Assessment
KASE-AQ = Knowledge, Attitude, and Self
Efficacy Asthma Questionnaire
MDI = Metered Dose Inhaler
NC = Nebulizer Chronolog
PC = Personal Computer
SABA = Short-Acting Beta Agonists
USB = Universal Serial Bus
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